跳至主要内容
临床试验/NCT03508817
NCT03508817Unknown早期 1 期

Randomized Clinical Trial on Atropine 0.01% for the Control of Myopia in Omani Children

Sultan Qaboos University1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2018年12月20日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
入组人数
150
试验地点
1
主要终点
The primary outcome is progression of myopia

研究概览

简要总结

Control of myopia progression has become an important goal because of concerns regarding significantly increased risks of retinal degeneration, retinal detachment, glaucoma and cataract associated with high myopia. It is also clear there prevalence of myopia in children and young adults is increasing all over the world. Several methods including use of progressive addition lenses, rigid gas-permeable contact lenses, and life-style modifications (increased outdoor activity) have reported to alter myopia progression with varying efficacy. In general they have yielded clinical results of marginal significance. Atropine sulphate eye drops has consistently been demonstrated to inhibit axial myopia progression in both humans and animal models. Yet it has not found widespread clinical application for myopia control due to ocular side-effects of cycloplegia and pupil dilation. Recently 0.01% atropine has been shown to be effective in arresting myopia progression without side-effects of cycloplegia and near vision impairment and pupil dilatation and increased light sensitivity. Almost all studies on atropine have been carried out on children of Chinese origin. Efficacy (concentration and dosing) and safety need to be established in the population of interest, before routine use can be recommended. We plan to evaluate the efficacy and safety of topical 0.01% atropine eye drops in slowing the progression of myopia and ocular axial elongation in Omani children. A total of 150 children of ages 6-16 years will be randomized to two groups. Intervention group will receive atropine 0.01% once daily in each eye for two years (Phase 1). Control group will not receive any medications. Follow up visits will be scheduled every three months in Phase 1. Subsequently, medication will be stopped and the study patients will be followed up every six months for one year (Phase 2). The progression of myopia (change in refractive error and axial length) will be compared in the two groups by objective methods.

详细描述

To assess the efficacy and safety of using 0.01% atropine eye drops in reducing the progression of myopia in Omani population.

Objectives:

  • To compare the effect of 0.01% atropine eye drops on progression of myopic refractive error and axial length with that in the control group.
  • To study the effect of 0.01% atropine eye drops on pupil dilatation
  • To study the effect of 0.01% atropine eye drops on amplitude of accommodation
  • To study the effect of 0.01% atropine eye drops on near visual acuity
  • To study the effect of 0.01% atropine eye drops on glare, photophobia and contrast senstivity

Research Methodology

Study design: Randomized, interventional, clinical trial.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
6 Years 至 15 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Age: 6 to 15 years
  • Myopia ≥ 2.00 D (cycloplegic refraction; spherical equivalent)
  • No prior or current treatment for preventing myopia progression (bifocals / progressive addition lenses / orthokeratology)

排除标准

  • Best corrected visual acuity < 0.5 (6/12)
  • Refractive Myopia
  • Astigmatism ≥ 1.5 D
  • Amblyopia
  • Ocular hypertension / Glaucoma
  • Prior intraocular surgery
  • Allergy to atropine eye drops
  • Systemic diseases associated with myopia such as Marfan syndrome, Stickler syndrome
  • History of cardiac or significant respiratory diseases
  • Lack of consent for participating in the study

研究组 & 干预措施

Atropine Sulfate 0.01% Eye Drops Group

Experimental

Intervention group will receive atropine sulphate eye drops 0.01% once nightly for 2 years.

干预措施: Atropine Sulfate 0.01% Eye Drops (Drug)

结局指标

主要结局

The primary outcome is progression of myopia

时间窗: 2 years

defined as the change in spherical equivalent refractive error (SER) relative to baseline

次要结局

  • change in axial length(2 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Anuradha Ganesh

Senior Consultant

Sultan Qaboos University

研究点 (1)

Loading locations...

相似试验